Ready et al. found that non-small cell lung cancer patients with high TMB had better response rate and prolonged progression-free survival when treated with nivolumab plus low-dose ipilimumab despite PD-L1 expression [33]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.